Tack Optimized Balloon Angioplasty Below the Knee (TOBA - BTK) Study

Peripheral Artery Disease Clinical Trial

— TOBABTK  

Official title:

Prospective, Multicenter Tack Optimized Balloon Angioplasty Below the Knee (TOBA - BTK) Study for Infrapopliteal Arteries Using the Tack-It Endovascular System™

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02235675
• Other study ID #: TD 0109
• Status: Completed
• Phase: N/A
• Start date: December 2013
• Est. completion date: February 2017

Study information

• Verified date: April 2021
• Source: Philips Clinical & Medical Affairs Global
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multi-center study to optimize below the knee (BTK) balloon angioplasty results by creating tissue apposition in peripheral arteries with Reference Vessel Diameter's (RVD) ranging from 1.5mm to 4.5mm.

Description:

This first in man (FIM) study is to collect data in support of the safety and performance of the Intact Vascular Tack-It Endovascular System™ for tissue apposition to optimize balloon angioplasty.

Study primary endpoints:

Safety: Composite of Major Adverse Limb Events (MALE) and Peri-procedural Death (POD), assessed at 1 month. Endpoint includes any of the following:

• Major amputation - amputation above the ankle

• Re-intervention (surgical or endovascular) in the target limb

• Procedure-related death - any death within 1 month of the index procedure or any MALE

Device Success: The achievement of successful delivery and deployment of the study device(s) at the intended target site(s) and successful withdrawal of the delivery catheter.

Technical Success: Device success (defined above) and the ability of the Tack to resolve post-PTA dissection, demonstrating angiographic patency at the conclusion of the procedure.

Clinical Success: Ability of the Tack to resolve post-PTA dissection and achieve patency at the conclusion of the procedure, without procedure related complications within 48 hours after the index procedure or at hospital discharge, whichever is sooner.

Study secondary endpoints:

The following events will be assessed at 3, 6 and 12 months:

• All-cause mortality

• Amputation of the limb (above the ankle)

• Amputation free survival

• Clinically driven target vessel revascularization (TVR)

• Clinically driven target lesion revascularization (TLR)

• Changes in Rutherford Clinical Category from baseline

The following parameters will be assessed at 1, 3, 6 and 12 months:

• Maintenance of luminal patency of the target lesion by TBI (≤0.15 decrease) as compared to the baseline TBI obtained prior to discharge

• Doppler Exam (presence of signal)

Study observational endpoint:

The following parameter will be assessed at 6 months (Per local Standard of Care):

• Angiographic percent diameter stenosis

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: February 2017
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age of subject is >18

• Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the consent form

• Subject has critical limb ischemia (CLI)

• Subject has Rutherford Clinical Category 4-5. (hemodynamic reference)

• Reference vessel diameter below the knee (BTK) is between 1.5mm and 4.5mm (inclusive).

• De-novo target lesion(s) has stenosis >70%.

• Must be able to perform PTA. The PTA must result in a dissection Type A - F at some location along the treatment site.

• Any vessel intervened on must have distal reconstitution above the ankle.

• Inflow Iliac, SFA and Popliteal lesions can be treated during the same procedure using standard angioplasty and/or an approved device. These inflow lesions must be treated first, prior to consideration of treatment of BTK lesions. The patient can be enrolled if the inflow lesions are treated with good angiographic results (must have <30% residual stenosis and no evidence of embolization).

Key Exclusion Criteria:

• The subject has a lesion on the plantar surface of the heel or over the Achilles tendon or has exposed calcaneus.

• The subject has extensive forefoot gangrene / ischemic ulcer that cannot be resolved with standard metatarsal amputation.

• Previous treatment failure of inflow arteries (Iliac, SFA and Popliteal)

• Subject with below knee bypass.

• Subject has significant stenosis or occlusion of inflow vessels tract (proximal disease) not successfully treated (>30% residual stenosis and/or complication of the procedure) prior to BTK angioplasty and patient enrollment.

• Subject is permanently wheel-chair bound or bedridden.

• Subject has an allergy to contrast medium that cannot be pretreated.

• Episode of acute limb ischemia within the previous 30 days.

• Subject is undergoing atherectomy in the target limb or cryoplasty or stenting of BTK treatment site.

• Subject has a systemic infection with positive blood cultures/bacteremia within one week.

• Subject has undrained pus or spreading wet gangrene in the foot that is not controlled at the time of revascularization procedure.

• Subject in whom antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated.

• Myocardial infarction within 30 days prior to enrollment.

• History of stroke within 180 days prior to enrollment.

• Subject has acute or chronic renal disease (e.g., as measured by a serum creatinine of >2.5 mg/dL or >220 umol/L).

• Subject has a known hypersensitivity or contraindication to nitinol.

Related Conditions & MeSH terms

• Critical Limb Ischemia
• Ischemia
• Peripheral Arterial Disease
• Peripheral Artery Disease

Intervention

Device:
• Tack-It Endovascular System
Repair of post-PTA dissections using the Intact Vascular Tack-It implant.

Locations

Country	Name	City	State
Austria	Medizinische Universitat Graz	Graz

Sponsors (1)

Lead Sponsor	Collaborator
Philips Clinical & Medical Affairs Global

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Observational Endpoint	The following parameter will be assessed at 6 months (Per local Standard of Care): • Angiographic percent diameter stenosis	6 Months
Primary	Primary Endpoints	Safety: Composite of Major Adverse Limb Events (MALE) and Peri-procedural Death (POD), assessed at 1 month. Endpoint includes any of the following: Major amputation - amputation above the ankle; Re-intervention (surgical or endovascular) in the target limb; Procedure-related death - any death within 1 month of the index procedure or any MALE	30 Days
Secondary	Secondary Endpoints	The composite of following events will be assessed at 3, 6 and 12 months or as noted: All-cause mortality; Amputation of the limb (above the ankle); Amputation free survival; Clinically driven target vessel revascularization (TVR); Clinically driven target lesion revascularization (TLR); Changes in Rutherford Clinical Category from baseline; Maintenance of luminal patency of the target lesion by TBI (=0.15 decrease) as compared to the baseline TBI obtained prior to discharge at 1,3,6 and 12 months.; Doppler Exam (presence of signal at 1,3,6 and 12 months)	1, 3, 6 and 12 Months